KANEKA
Kaneka Corporation (TOKYO:4118) has released KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y), a real-time PCR test kit capable of simultaneously detecting four variants of COVID-19. The new kit has a suggested retail price of 217,800 yen, including tax, and is available for purchase starting from September 30.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211010005005/en/
This test kit uses a reagent developed using Kaneka's molecular testing-related technologies. The reagent makes it possible to simultaneously detect four mutations*1 of spike protein (the N501Y, E484K, E484Q, and L452R mutations) with a single PCR test. Based on the mutation detection patterns, it can efficiently detect*2 variants (the Alpha, Delta, Kappa, and Beta or Gamma variants).
The PCR kit for detecting COVID-19 released by Kaneka last year received approval in June of this year as "KANEKA Direct RT-PCR kit SARS-CoV-2" for use as an In-Vitro Diagnostic reagent. It is widely used in medical facilities and testing centers. By adding this new COVID-19 variant PCR test kit to our lineup, we are contributing to the rapid detection of variants and the prevention of the spread of COVID-19.
Kaneka is taking a wide range of measures to combat COVID-19. These include the launching of the “Infection Initiative Team,” which conducts research and development regarding infection control measures including COVID-19, performing contract manufacturing of DNA vaccine APIs and intermediates, supplying the API used in “AviganTM ”, developing antibody drugs, supplying PCR testing reagents and testing kits, and shipping vaccine using temperature controlled packages.
*1. These refer to mutations of the amino acids in viral spike proteins. The names are based on the mutation. In the N501Y mutation, the 501st amino acid in the spike protein has changed from N (asparagine) to Y (tyrosine). In the E484K mutation, the change was from E (glutamine acid) to K (lysine). In E484Q, it was from E (glutamine acid) to Q (glutamine). In L452R, it was from L (leucine) to R (arginine).
*2. Relationship between detected COVID-19 mutations and variants (+: positive, -: negative)
This product cannot distinguish Beta variants from Gamma variants.
N501Y |
E484K |
E484Q |
L452R |
Determination |
|
+ |
- |
- |
- |
==> | Alpha variant |
- |
- |
- |
+ |
==> | Delta variant |
- |
- |
+ |
+ |
==> | Kappa variant |
+ |
+ |
- |
- |
==> | Beta or Gamma variant |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211010005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Original “Titanic Cherub” From James Cameron’s Epic Film Heads to Auction December 9 & 1024.11.2025 21:48:00 CET | Press release
Iconic Hollywood Artifact Indelibly Linked with “Jack & Rose” Portrayed by Kate Winslet and Leonardo DiCaprio One of the most recognizable and beloved set pieces from James Cameron’s Titanic heads to auction on December 9 &10 —the original Grand Staircase Cherub, seen in multiple scenes of the 1997 blockbuster, including the pivotal moment when Jack and Rose meet in front of the First Class Dining Room and the climactic moment when the Atlantic Ocean bursts through the skylight and floods the staircase, and cherub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124056883/en/ The iconic “cherub” with Leonardo DiCaprio & Kate Winslet in James Cameron’s “TITANIC”. The ornate fixture—crafted for the full-scale recreation of Titanic’s Grand Staircase—was gifted by the production to Martin Biallas, CEO of SEE Global Entertainment, whose immersive exhibitions have brought the world’s most famous ship to millions of fans. It now
Access Advance Announces Major Growth in Its HEVC and VVC Patent Pools24.11.2025 16:10:00 CET | Press release
Access Advance LLC today announced significant expansions of both its HEVC Advance and VVC Advance Patent Pools during the second and third quarters of 2025, underscoring continued industry confidence in the company's balanced and transparent approach to video codec licensing. This growth follows the successful January 2025 launch of Access Advance's Video Distribution Patent ("VDP") Pool, demonstrating the company's expanding role in comprehensive video codec patent licensing solutions. Among the many highlights, Sharp Corporation joined the HEVC Advance Patent Pool as a Licensor, bringing valuable intellectual property assets to the pool's already extensive patent portfolio. Additionally, Huawei Technologies Co., Ltd., already an HEVC Advance Licensor and Licensee, expanded its collaboration with Access Advance by joining the VVC Advance Patent Pool as a Licensee. HP Inc. also expanded its license to include the VVC Advance Patent Pool after previously joining HEVC Advance in 2024, w
Microsize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in Switzerland24.11.2025 15:05:00 CET | Press release
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124545344/en/ The agreement represents Microsize’s second acquisition from Lonza, following the successful 2022 divestment of its Quakertown, Pennsylvania site. In this transaction, Schedio Group – a Swiss-based provider of jet mills, isolators, spray dryers, and engineering services – is investing alongside Microsize to strengthen and localize its operational base in Europe, advancing a shared vision to lead the next generation of integrated particle engineering solutions. With more than 30 years of experience, Mic Mac has served the pharmaceutical industry with proven GMP-compliant jet milling and micronization capabilities for b
Hytera to Debut S1 E at PMRExpo 202524.11.2025 14:17:00 CET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, today introduced the S1 E, a business-ready, palm-sized two-way radio designed specifically for the retail sector, expanding the portfolio of S Series and providing one more option for retail users to choose for their daily operations. The S1 E will make its debut at PMRExpo, the Europe's premier trade fair for secure, mission- and business-critical communication, taking place from November 25th to 27th, 2025, at Koelnmesse in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124768341/en/ Hytera New Released Licence-free Analogue Business Radio S1 E Adhering to the S Series’ signature design language, the S1 E combines a stylish, modern, and minimalist aesthetic with practical functionality. Weighing under 85g, the S1 E provides all-day wearing comfort without tugging or weighing down uniforms. Key enhancements and sta
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 14:00:00 CET | Press release
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia GravisCladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDAMerck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
